168 research outputs found
Computing the Goodwillie-Taylor tower for discrete modules
No full textA functor from finite sets to chain complexes is called atomic if it is completely determined by its value on a particular set. We present a new resolution for these atomic functors, which allows us to easily compute their Goodwillie polynomial approximations. By a rank filtration, any functor from finite sets to chain complexes is built from atomic functors. Computing the linear approximation of an atomic functor is a classic result involving partition complexes. Robinson constructed a bicomplex, which can be used to compute the linear approximation of any functor. We hope to use our new resolution to similarly construct bicomplexes that allow us to compute polynomial approximations for any functor from finite sets to chain complexes.Submission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2019-08-01The student, Amelia Tebbe, accepted the attached license on 2017-07-11 at 14:57.The student, Amelia Tebbe, submitted this Dissertation for approval on 2017-07-11 at 15:10.This Dissertation was approved for publication on 2017-07-11 at 15:51.DSpace SAF Submission Ingestion Package generated from Vireo submission #11402 on 2017-09-29 at 11:18:54Made available in DSpace on 2017-09-29T16:39:45Z (GMT). No. of bitstreams: 2
TEBBE-DISSERTATION-2017.pdf: 440856 bytes, checksum: 4fed866700ce11d8c74574bc4629721c (MD5)
LICENSE.txt: 4209 bytes, checksum: 535008da6959876749f421a795e797af (MD5)
Previous issue date: 2017-07-11Embargo set by: Colleen Fallaw for item 103423
Lift date: 2019-09-29T16:39:52Z
Reason: Author requested closed access (OA after 2yrs) in Vireo ETD systemEmbargo set by: Colleen Fallaw for item 103423
Lift date: 2019-09-29T17:52:45Z
Reason: Author requested closed access (OA after 2yrs) in Vireo ETD systemLimited Restriction Lifted for Item 103423 on 2019-09-30T09:15:20Z
Chronic beta-blocker therapy in patients with coronary artery disease is without influence on plasma lipids: a multivariate analysis
No full textChronic beta-blocker therapy in patients with coronary artery disease is without influence on plasma lipids: a multivariate analysis
No full textA Global Perspective on Blood Pressure Treatment and Control in a Referred Cohort of Hypertensive Patients
No full textHypertensive patients with cardiovascular (CV) comorbidities are at increased risk, and cardiologists' care should put particular emphasis on controlling blood pressure. Data on blood pressure treatment and control and drug utilization on a global scale, however, are scarce. Aiming to resolve this lack of information, the authors analyzed the data of International Survey Evaluating Microalbuminuria Routinely by Cardiologists in Patients With Hypertension (i-SEARCH) to gain further insights into national and regional blood pressure control and antihypertensive pharmacotherapy prescribed in cardiology practice. A total of 22,282 patients with hypertension from 26 countries were enrolled in 2005/2006. A total of 18,652 patients were treated (mean age, 63.0 +/- 11.4 years; 52.2% male; mean body mass index, 28.9 kg/m2). Mean systolic blood pressure was 148.2 +/- 19.8 mm Hg and diastolic blood pressure was 86.7 +/- 11.6 mm Hg. Blood pressure was controlled in 8.3% of diabetic and 25.3% of nondiabetic patients (21.2% overall), with particularly good control rates in North and Latin America (28.0% and 30.6%, respectively). A total of 31.2% of patients were treated with 1, 39.7% with 2, and 29.1% with >= 3 drugs. beta-Blockers were being used most frequently (47.9%), in both monotherapy and combination therapy despite low numbers of patients with respective compelling indications for their use. The present data illustrate the potential for an improvement of blood pressure treatment and control in daily cardiology practice. J Clin Hypertens (Greenwich). 2010; 12: 666-677. (C) 2010 Wiley Periodicals, Inc
Patients with coronary artery disease homozygous for the B-allele of high-density lipoprotein (HDL) paraoxonase (PON1) exhibit reduced HDL-PON1 arylesterase activities of HDL subfractions HDL2 and HDL3
No full textPatients with coronary artery disease homozygous for the B-allele of high-density lipoprotein (HDL) paraoxonase (PON1) exhibit reduced HDL-PON1 arylesterase activities of HDL subfractions HDL2 and HDL3
No full textNierenarterienstenose: Intervention oder medikamentöse Behandlung?
No full textBackground and objective: Angioplasty in patients with renal artery stenosis aims at reducing blood pressure and at improving kidney function. Its efficacy has however been questioned by recent published data. It was the aim of this retrospective study to compare angioplasty with medical treatment in an unselected patient population. Methods: Data on 109 patients were retrospectively anlysed. This cohort included all those patients admitted to the Lippe-Detmold Hospital between 1992 and 2008 for renal artery stenosis. The data included blood pressure, creatinine-based calculated glomerular filtration rate (cGFR), any renal dialysis, cardiovascular risk factors, events and survival time after transluminal renal angioplasty or drug treatment, respectively. Results: Patients who had undergone angioplasty were younger (p = 0.04), had less cardiovascular co-morbidity (p < 0.01), but a higher degree of stenosis (p < 0.01). After a median follow-up of 32.5 (angioplasty) and 36.0 months (drug treatment), respectively, a significant decrease of cGFR was recorded in drug treated patients (- 16.2 ml/min, 95%, CI - 25.7 to - 6.7) but not in the angioplasty group (- 4.5 ml/min, 95%, CI - 13.5 to 4.5). There were no other significant differences were not observed. Conclusion: Younger patients with a high degree of renal artery stenosis but without generalized atherosclerosis more frequently underwent angioplasty in clinical practice. The smaller post-angioplasty reduction in the loss of renal function in this group needs to be validated in a prospective, randomized study
Analytische und experimentelle Charakterisierung eines auf Flüssigkristall basierenden Phased Arrays
No full textThis dissertation analyzes the suitability of liquid crystal based phase shifters in a waveguide design for the use in a phased array antenna on a relay satellite in a geostationary orbit.Four key issues are addressed:1) The influence of the phase shifters on the array performance in a realistic use scenario.2) The envisioned manufacturing method for an integrated phase shifter.3) The characterization of the phase shifter performance.4) The characterization of a 4x1 array in a static and a dynamic environment.Despite the high transmission losses, analytical and experimental characterizations showed the suitability for the desired application.Diese Dissertation analysiert die Eignung von flüssigkristallbasierten Phasenschiebern in Hohlleiterbauweise welche in einer Phased-Array-Antenne auf einem geostationären Satelliten eingesetzt werden sollen.Vier Hauptpunkte werden hierbei adressiert:1) Der Einfluss der Phasenschieber auf die Arrayperformanz in einem realistischen Anwendungsszenario.2) Die angedachte Fertigungsmethode für einen integrierten Phasenschieber.3) Die Charakterisierung der Phasenschieberperformanz von verschiedentlich gefertigten Phasenschiebern und bei verschiedenen Temperaturen.4) Die Charakterisierung eines 4x1 Arrays in einer statischen und einer dynamischen Umgebung.Abgesehen von den hohen Transmissionsverlusten, zeigten die analytischen und experimentellen Charakterisierungen die Eignung für die angedachte Anwendung auf
Desmoteplase in acute massive pulmonary thromboembolism
No full textAlteplase is standard therapy for patients with acute, massive pulmonary embolism. The novel plasminogen activator desmoteplase displays high fibrin specificity and selectivity for fibrin-bound plasminogen. In a preclinical model desmoteplase was twice as potent with a shorter lysis time and lower reocclusion rate. We conducted a phase II study comparing 125, 180, and 250 mu g/kg bodyweight desmoteplase with 100 mg alteplase. Efficacy criteria were total pulmonary resistance (TPR), mean pulmonary artery pressure (mPAP), and Miller Index. Intention to treat analysis of 34 patients. The reduction of TPR after 24 hours was comparable between desmoteplase 180 mu g/kg and alteplase (-48.0 +/- 22.4 vs. -50.4 +/- 16.3%; p = n.s. vs. alteplase; p = 0.0002 and p<0.0001 vs. baseline). The greatest effect was achieved with desmoteplase 250 mu g/kg (-56.0 +/- 29.4%; p = n.s. vs. alteplase, p = 0.0055 vs. baseline). Two hours after treatment PAP was reduced by 27.9 (p = 0.0004 vs. baseline) and 30.4% (p = 0.015 vs. baseline) with the higher doses of desmoteplase and 29.6% with alteplase (p = 0.0006 vs. baseline). Further PAP reduction after 6 hours was most pronounced in the desmoteplase 250 mu g/kg group (-40.1 +/- 18.0%; p = 0.0028 vs. baseline). The reduction of the Miller Index was greatest using desmoteplase 250 mu g/kg (-35.0 +/- 21.7%; p = 0.011 vs. baseline), and alteplase (-41.6 +/- 27.2%; p = 0.0003 vs. baseline). Safety did not differ among the 4 groups. The study results suggest that desmoteplase at doses of 180 and 250 mu g/kg had similar or greater efficacy compared to alteplase 100 mg. Onset of action was faster, safety was comparable,PAION Deutschland GmbH, Aachen, German
Das Verhalten von Myokard- und Ventrikelfunktion unter Belastung bei verschiedenen Herzerkrankungen mit 25 Tabellen
No full text- …
